Saxenta brain study: unlocking weight loss secrets

NCT ID NCT02944500

Ongoing Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the weight-loss drug Saxenda (liraglutide) changes brain activity related to appetite. Researchers will scan the brains of 28 obese adults to see how they respond to food cues after treatment. The goal is to understand the underlying mechanisms that help people lose weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liraglutide (Saxenda)
What this could lead to: If successful, this could explain how Saxenda helps control appetite in the brain, potentially improving weight loss treatments.
What could go wrong: This is a small, early-phase study with only 28 participants, so results may not apply to everyone. It focuses on brain activity, not long-term weight loss or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center General Clinical Research Center

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.